Implantation of tumoral XC cells induces chronic, endothelin-dependent, thermal hyperalgesia in mice.
1. We describe here the alterations in the nociceptive sensitivity of Swiss CD1 mice receiving an intraplantar (i.pl.) administration of XC Rous sarcoma-virus-transformed rat fibroblasts (XC cells). 2. Histological studies reveal that XC cells remain at the injection site 2-3 weeks after implantation, a time at which an inflammatory reaction is also detected. No tumoral growth was found and 5 weeks after inoculation neither XC cells nor inflammatory reaction were observed. 3. Measures to different types of noxious stimuli were performed. At week 1 after XC cell inoculation, hyperalgesia to thermal, but not mechanical, stimuli as well as to capsaicin injection is present in the implanted paw. At week 5 after XC cell implantation, only thermal hyperalgesia is present, and this enhanced reactivity persisted for even 25 weeks after the disappearance of XC tumoral cells. 4. Pharmacological studies on thermal hyperalgesia were conducted at two different stages, week 1 and week 5 after XC cell inoculation. The systemic administration of morphine (1-10 mg/kg i.p. (intraperitoneal); 30 min before testing) prevents this thermal hyperalgesic reaction both at week 1 and week 5. The endothelin type A (ETA) receptor antagonist BQ-123 (10 nmol; i.pl.; 90 min before testing) abolishes both the early (week 1) and the late (week 5) thermal hyperalgesia. In contrast, the selective endothelin type B (ETB) receptor antagonist, BQ-788 (10 nmol; i.pl.; 90 min before) abolishes thermal hyperalgesia only at week 1, but not at week 5 after XC cell inoculation. 5. It might be concluded that endothelins are probably involved in this type of long-term thermal hyperalgesia produced by the transitory presence of the XC tumoral cell line.
Baamonde
Ana
A
Laboratorio de Farmacología, Facultad de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain. arbaiza@correo.uniovi.es
Lastra
Ana
A
Fresno
Manuel F
MF
Llames
Sara
S
Meana
Alvaro
A
Hidalgo
Agustín
A
Menéndez
Luis
L
D000818:Animals; D001358:Avian Sarcoma Viruses / Q000235:genetics; D002211:Capsaicin / Q000494:pharmacology; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D002908:Chronic Disease; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000378:metabolism*; D005347:Fibroblasts / Q000473:pathology / Q000637:transplantation*; D005822:Genetic Vectors / Q000235:genetics; D006614:Hindlimb / Q000473:pathology; D006930:Hyperalgesia / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D007249:Inflammation / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D051379:Mice; D009020:Morphine / Q000494:pharmacology; D009365:Neoplasm Regression, Spontaneous / Q000473:pathology; D009368:Neoplasm Transplantation; D009619:Nociceptors / Q000187:drug effects / Q000502:physiology; D009842:Oligopeptides / Q000494:pharmacology; D010147:Pain Measurement; D010456:Peptides, Cyclic / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D017466:Receptors, Endothelin / Q000378:metabolism
D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D017466:Receptors, Endothelin; C086539:BQ 788; D009020:Morphine; D002211:Capsaicin; C072247:cyclo(Trp-Asp-Pro-Val-Leu)